Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tarsus Pharmaceuticals (TARS) EBIT: 2020-2024

Historic EBIT for Tarsus Pharmaceuticals (TARS) over the last 5 years, with Dec 2024 value amounting to -$120.6 million.

  • Tarsus Pharmaceuticals' EBIT rose 42.26% to -$14.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$87.4 million, marking a year-over-year increase of 37.83%. This contributed to the annual value of -$120.6 million for FY2024, which is 15.78% up from last year.
  • According to the latest figures from FY2024, Tarsus Pharmaceuticals' EBIT is -$120.6 million, which was up 15.78% from -$143.2 million recorded in FY2023.
  • In the past 5 years, Tarsus Pharmaceuticals' EBIT ranged from a high of -$12.2 million in FY2021 and a low of -$143.2 million during FY2023.
  • Moreover, its 3-year median value for EBIT was -$120.6 million (2024), whereas its average is -$108.8 million.
  • Its EBIT has fluctuated over the past 5 years, first soared by 54.97% in 2021, then crashed by 415.85% in 2022.
  • Tarsus Pharmaceuticals' EBIT (Yearly) stood at -$27.0 million in 2020, then surged by 54.97% to -$12.2 million in 2021, then crashed by 415.85% to -$62.7 million in 2022, then plummeted by 128.28% to -$143.2 million in 2023, then grew by 15.78% to -$120.6 million in 2024.